AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2020
Jan 3, 2020
31523_dirs_2020-01-03_2de893fb-3446-4da8-925d-319c11808ea6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-12-31
Reporting Person: Rosenberg Ellen (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Common Stock | F | 10131 | $9.74 | Disposed | 143334 | Direct |
| 2020-01-02 | Common Stock | A | 68446 | — | Acquired | 211780 | Direct |
| 2020-01-02 | Common Stock | S | 10448 | $9.5601 | Disposed | 201332 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-02 | Stock Options (right to buy) | $9.55 | A | 107575 | Acquired | 2030-01-02 | Common Stock (107575) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15000 | Indirect |
Footnotes
F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.50 to $9.61. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.